BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:21 PM
 | 
Mar 20, 2007
 |  BC Extra  |  Clinical News

Corcept down on third failed Phase III

CORT fell $0.14 (13%) to $0.90 on Tuesday after Corlux mifepristone missed the primary endpoint in a double-blind, U.S. and European Phase III trial to treat psychotic features of psychotic major depression (PMD). The primary endpoint of Study 06...

Read the full 180 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >